4D Molecular Therapeutics Inc
Gene therapy vectors and gene therapeutic products for treating genetic and acquired diseases
Follows are private to you and power your alerts
Updated · 4dmoleculartherapeutics.com
- Sector
- Biotech
- Headquarters
- EMERYVILLE, CA
- Founded
- 2015
- Latest Form D
- $90M, Sep 2018
- Total capital
- $109M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $109M
- 3 Form D · last Sep 2018
- 98 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2021
- Rank in peer group#89 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$90M
- Private capital raisedForm D · SEC · 2nd filing$11.6M
- Private capital raisedForm D · SEC · 1st filing$7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#89 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Charles Theuer, Ph.D.DirectorNamed in SEC Form D filings
- David KirnExecutive Officer, DirectorNamed in SEC Form D filings
- David Kirn, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- David SchafferDirectorNamed in SEC Form D filings
- David Schaffer, Ph.D.,Executive Officer, DirectorNamed in SEC Form D filings
- Hoyoung Huh, M.D., Ph.D.DirectorNamed in SEC Form D filings
Show all 13 people
- Leisa Johnson, Ph.D.Executive OfficerNamed in SEC Form D filings
- Margi McLaughlinDirectorNamed in SEC Form D filings
- Margi McLoughlinDirectorNamed in SEC Form D filings
- Peter Francis, M.D.Executive OfficerNamed in SEC Form D filings
- Sharon TetlowDirectorNamed in SEC Form D filings
- Theresa JankeExecutive OfficerNamed in SEC Form D filings
- Tony YaoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- PendingTreatments for Ocular NeovascularizationUSPTOApplication 19629274
- GrantedTreatments for Ocular NeovascularizationUSPTOUS 12,599,680
- PendingAdeno-associated Virus Variant Capsids With Improved Retinal Transduction And Uses ThereofUSPTOApplication 19301643
Show all 40 patent records
- Treatments for Ocular NeovascularizationJul 23, 2026 · Application 19629274Pending
- Treatments for Ocular NeovascularizationApr 14, 2026 · US 12,599,680Granted
- Adeno-associated Virus Variant Capsids With Improved Retinal Transduction And Uses ThereofFeb 26, 2026 · Application 19301643Pending
- Adeno-Associated Virus Variant Capsids with Improved Lung Tropism and Uses ThereofJan 15, 2026 · Application 18844861Pending
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofMay 22, 2025 · Application 18978736Pending
- Compositions and Methods for Treatment of Ocular Disease Associated with AngiogenesisFeb 20, 2025 · Application 18767370Pending
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofFeb 11, 2025 · US 12,221,616Granted
- Codon Optimized REP1 Genes And Uses ThereofOct 31, 2024 · Application 18766963Pending
- Adeno-associated Virus Variant Capsids And Use For Inhibiting AngiogenesisOct 10, 2024 · Application 18466517Pending
- Compositions and Methods for Treatment of Ocular Disease Associated with AngiogenesisApr 25, 2024 · Application 18482628Pending
- Adeno-associated Virus Variant Capsids With Improved Retinal Transduction And Uses ThereofFeb 29, 2024 · Application 18447866Pending
- Adeno-associated Variants, Formulations And Methods For Pulmonary DeliveryFeb 29, 2024 · Application 18468142Pending
- Codon Optimized Gla Genes And Uses ThereofJan 18, 2024 · Application 18463979Pending
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofDec 12, 2023 · US 11,840,704Granted
- Adeno-associated Variants, Formulations And Methods For Pulmonary DeliveryNov 7, 2023 · US 11,807,868Granted
- Codon Optimized Gla Genes And Uses ThereofOct 31, 2023 · US 11,802,278Granted
- Codon Optimized RPGRORF15 Genes And Uses ThereofOct 26, 2023 · Application 18042517Pending
- Adeno-associated Virus Variant Capsids And Use For Inhibiting AngiogenesisSep 26, 2023 · US 11,766,489Granted
- Treatments For Retinal DiseaseSep 26, 2023 · US 11,766,487Granted
- Codon Optimized REP1 Genes And Uses ThereofMay 25, 2023 · Application 18052735Pending
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofMar 28, 2023 · US 11,613,766Granted
- Treatments For Retinal DiseaseFeb 14, 2023 · US 11,576,983Granted
- Codon Optimized REP1 Genes And Uses ThereofDec 13, 2022 · US 11,524,081Granted
- Adeno-associated Variants, Formulations And Methods For Pulmonary DeliveryNov 15, 2022 · US 11,499,166Granted
- Codon Optimized RPGRORF15 Genes And Uses ThereofSep 15, 2022 · Application 17825665Pending
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofAug 23, 2022 · US 11,419,949Granted
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofJun 21, 2022 · US 11,364,308Granted
- Codon Optimized REP1 Genes And Uses ThereofJun 14, 2022 · US 11,357,870Granted
- Codon Optimized RPGRORF15 Genes And Uses ThereofMay 31, 2022 · US 11,345,930Granted
- Codon Optimized Gla Genes And Uses ThereofDec 14, 2021 · US 11,198,858Granted
- Method Of Using Adeno-associated Virus With Variant CapsidNov 23, 2021 · US 11,179,477Granted
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofNov 9, 2021 · US 11,167,041Granted
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofSep 14, 2021 · US 11,118,192Granted
- Adeno-associated Virus Variant Capsids And Methods Of Use ThereofJun 17, 2021 · Application 17163038Pending
- Aav Variants For Treatment Of Complement DisordersApplication PCTUS2024022843Pending
- Methods for Treating Wet Age-Related Macular Degeneration with Adeno-Associated VirusApplication 63736368Pending
- AAV Variants with Improved CNS Tropism and Uses ThereofApplication 63641775Pending
- Novel Complement System Inhibiting AntibodiesApplication PCTUS2024030542Pending
- Methods for Treating Diabetic Macular Edema with Adeno-Associated VirusApplication 63743293Pending
- Compositions And Methods For Selective Gene Expression In The Treatment Of Ocular DiseaseApplication PCTUS2026015529Pending
Related companies, and why
- SOLVEXA, LLCSimilar federal contract value in Biotech · null in contracts
- HASENTECH, INC.Similar federal contract value in Biotech · null in contracts
- Third Arc Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Pyxis OncologySimilar federal contract value in Biotech · null in contracts
- Imago BioSciencesSimilar federal contract value in Biotech · null in contracts
- Dianthus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .